Uso oral de Lactobacillus rhamnosus GG associado a oclacitinib em cães com dermatite atópica canina

Abstract

Canine atopic dermatitis (CAD) is a chronic inflammatory disease influenced by the interaction of genetic and environmental factors. The aim of this study was to evaluate the efficacy of the combination of oclacitinib and oral Lactobacillus rhamnosus GG in reducing the severity of skin lesions and pruritus in dogs diagnosed with ACD. Forty privately owned, non-seasonally atopic dogs undergoing treatment with oclacitinib for at least four months were selected. The animals were divided into two randomized, double-blind groups of twenty individuals: one received L. rhamnosus GG and the other placebo. Clinical signs were assessed using the CADESI-04 scale and the owner-reported pruritus score (pVAS) on days 0, 45 and 90. Statistical analysis revealed significant reductions in CADESI-04 scores in the test group on day 45 (p = 0.049) and day 90 (p = 0.049) compared to the placebo group. The pVAS scores also had significant reductions in the test group on day 45 (p < 0.01). No adverse effects were observed during the study. The results demonstrated the potential clinical benefit of L. rhamnosus GG when combined with oclacitinib in the treatment of CAD. However, future studies with longer follow-up periods and more extensive and diverse participant groups could validate the efficacy and safety of this treatment approach. [resumo fornecido pelo autor]